Quantitative structure activity relationships in drug metabolism

Current Topics in Medicinal Chemistry

Volumn 6, Issue 15, 2006, Pages 1569-1578

  Chohan, Kamaldeep K ^a   Paine, Stuart W ^a   Waters, Nigel J ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

3D QSAR; ADME models; Bayesian neural networks; CYP 2B1; UGT isoform

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 1A2 INHIBITOR; CYTOCHROME P450 2C19; CYTOCHROME P450 2C19 INHIBITOR; CYTOCHROME P450 2C9; CYTOCHROME P450 2C9 INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DIAZEPAM; DRUG; DRUG METABOLIZING ENZYME; FLUVOXAMINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B4; IMIPRAMINE; MEPHENYTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROPRANOLOL; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTIFICIAL NEURAL NETWORK; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER MODEL; DRUG ABSORPTION; DRUG BINDING; DRUG CROSS REACTIVITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; ENZYME METABOLISM; FOOD DRUG INTERACTION; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR DYNAMICS; NONLINEAR SYSTEM; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GLUCURONOSYLTRANSFERASE; HUMANS; METABOLIC DETOXICATION, DRUG; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748101952     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778108960     Document Type: Review

References (61)

1. Hodgson J. ADMET - turning chemicals into drugs. Nat. Biotechnol. 2001, 19(8): 722-726.
2. Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001, 31, 557-89.
3. Minors, J. O.; Mackenzie, P. I. Drug glucuronidation in humans. Pharmacol. Ther. 1991, 51, 347-369.
4. Wrighton, S. A.; Stevens, J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992, 22, 1-21.
5. Winkler, D.A. The role of QSAR in biomolecular discovery. Brief. Bioinfo. 2002, 3, 73.
6. Long, A.; Walker, J. D. Quantitative structure-activity relationships for predicting metabolism and modelling cytochrome P450 enzyme activities. Envir. Toxicol. Chem. 2003, 22(8), 1894-1899.
7. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology 2003, 11(1), 43-73.
8. Smith, P. A.; Sorich, M. J.; Low, L. S. C.; McKinnon, R. A.; Miners, J. O.; Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases. J. Mol. Graph. Mod. 2004, 22, 507-517.
9. Wolbrette, D.L. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. Curr. Cardiol. Rep. 2004, 6(5), 379-384.
10. Ekins, S.; Bravi, G.; Wikel, J.H.; Wrighton, S.A. Three-Dimensional Quantitative Structure Activity Relationship (3D-QSAR) Analysis of CYP 3A4 Substrates. J. Pharmacol. Exp. Ther. 1999, 291, 424-433.
11. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J.S.; Ring, B.J.; Wikel, J.H.; Wrighton, S.A. Three- and Four-Dimensional Quantitative Structure Activity Relationship Analyses of Cytochrome P-450 3A4 Inhibitors. J. Pharmacol. Exp. Ther. 1999, 290, 429-438.
12. Wanchana, S.; Yamashita, F.; Hashida, M. QSAR Analysis of the Inhibition of Recombinant CYP 3A4 Activity by Structurally Diverse Compounds Using a Genetic Algorithm-Combined Partial Least Squares Method. Pharm. Res. 2003, 20, 1401-1408.
13. Molnar, L.; Keseru, G.M. A Neural Network Based Virtual Screening of Cytochrome P450 3A4 Inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 419-421.
14. de Groot, M.J.; Ackland, M.J.; Horne, V.A.; Alex, A.A.; Jones, B.C. Novel Approach to Predicting P450 Mediated Drug Metabolism. The Development of a Combined Protein and Pharmacophore Model for CYP2D6. J. Med. Chem. 1999, 42, 1515-1524.
15. Haji-Momenian, S.; Rieger, J.M.; Macdonald, T.L.; Brown, M.L. Comparative Molecular Field Analysis and QSAR on Substrates Binding to Cytochrome P450 2D6. Bioorg. Med. Chem. 2003, 11, 5545-5554.
16. Ekins, S.; Berbaum, J.; Harrison, R.K. Generation and Validation of Rapid Computational Filters for CYP2D6 and CYP3A4. Drug Metab. Disp. 2003, 31, 1077-1080.
17. Kemp, C.A.; Flanagan, J.U.; van Eldik, A.J.; Marechal, J-D.; Wolf, C.R.; Roberts, G.C.K.; Paine, M.J.I.; Sutcliffe, M.J. Validation of Model of Cytochrome P450 2D6: An in Silico Tool for Predicting Metabolism and Inhibition. J. Med. Chem. 2004, 47, 5340-5346.
18. Susnow, R.G.; Dixon, S.L. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition. J. Chem. Inf. Comput. Sci. 2003, 43, 1308-1315.
19. O'Brien, S.E.; de Groot, M.J. Greather Than the Sum of Its Parts: Combining Models for Useful ADMET Prediction. J. Med. Chem. 2005, 48, 1287-1291.
20. Hutzler, J.M.; Walker, G.S.; Wienkers, L.C. Inhibition of Cytochrome P450 2D6: Structure-Activity Studies Using a Series of Quinidine and Quinine Analogues. Chem. Res. Toxicol. 2003, 16, 450-459.
21. Brosen, K. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin. Pharmacokinet. 1995, 29, 20-25.
22. Guengerich, F. P.; Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991, 4, 391-407.
23. Jeppesen, U.; Loft, S.; Poulsen, H. E.; Broesen, K. A. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996, 6, 213-222.
24. So, F. V.; Guthrie, N.; Chambers, A. F.; Moussa, M.; Carroll, K. K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr. Cancer. 1996, 26, 167-181.
25. Wattenberg, L. W. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res. 1992, 52, 2085-2091.
26. Steinmetz, K. A.; Potter, J. D. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control. 1991, 2, 427-442.
27. Lewis, F. V.; Modi, S.; Dickins, M. Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochrome P450 Involved in Drug Metabolism. Drug Metabol. Drug Interact. 2001, 18, 221-242.
28. Moon, T.; Chi, M. H.; Kim, D.-H.; Yoon, C. N.; Choi, Y.-S. Quantitative Structure-Activity Relationships (QSAR) Study of Flavonoid Derivatives for Inhibition of Cytochrome P450 1A2. Quant. Struc.-Act. Relat. 2000, 19, 257-263.
29. Iori, F.; da Fonseca, R.; João Ramos, M.; Menziani, M. C. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorganic Med. Chem. 2005, 13, 4366-4374.
30. Chohan, K. K.; Paine, S. W.; Mistry, J.; Barton, P.; Davis, A. M. A Rapid Computational Filter for Cytochrome P450 1A2 Inhibition Potential of Compound Libraries. J. Med. Chem. 2005, 48, 5154-5161.
31. Korhonen, L, E.; Minna, R.; Mähönen, N. J.; Wittekindt, C.; Poso, A. Predictive Three-Dimensional Quantitative Structure-Activity Relationship of Cytochrome P450 1A2 Inhibitors. J. Med. Chem. 2005, 48, 3808-3815.
32. Rendic, S.; di Carlo, F. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug. Metab. Rev. 1997, 29, 413-580
33. Miners, J.; Birkett, D. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 1998, 45, 525-538.
34. Langowski, J.; Long, A. computer systems for the prediction of xenobiotic metabolism. Adv. Drug Delivery Rev. 2002, 54, 407-415.
35. Mancy, A.; Dijols, S.; Poli, S.; Guengerich, P.; Mansuy, D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 1996, 35, 16205-16212.
36. Takahashi, H.; Sato, T.; Shimoyama, Y.; Shioda, N.; Shimizu, T.; Kubo, S.; Tamura, N.; Tainaka, H.; Yasumori, T.; Echizen, H. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin. Pharmacol. Ther. 1999, 66, 569-581.
37. Locuson, C. W.; Wahlstrom, J. L.; Rock, D. A.; Rock, D. A.; Jones, J. P. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab. Dispos. 2003, 31, 967-971.
38. Lewis, D. F. V.; Dickins, M.; Weaver, R. J.; Eddershaw, P.J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization in the CYP2C subfamily. Xenobiotica 1998, 28, 235-268.
39. Afzelius, L.; Masimirembwa, C. M.; Karlen, A.; Andersson, T. B.; Zamora, I. Discriminant and qualitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. J. Comp.-Aided Mol. Design 2002, 16, 443-458.
40. Afzelius, L.; Zamora, I.; Masimirembwa, C. M.; Karlen, A.; Andersson, T. B.; Mecucci, S.; Baroni, M.; Cruciani, G. Conformer- and Alignment-Independent Model for Predicting Structurally Diverse Competitive CYP2C9 Inhibitors. J. Med. Chem. 2004, 47, 907-914.
41. Locuson, C. W.; Rock, D. A.; Jones, J. P. Quantitative Binding Models for CYP2C9 Based on Benzbromarone Analogues. Biochemistry, 2004, 43, 6948-6958.
42. Yap, C. W.; Chen, Y. Z. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. J. Chem. Inf. Model. 2005, 45, 982-992.
43. Locuson, C. W.; Suzuki, H.; Rettie, A. E.; Jones, J. P. Charge and Substituent Effects on Affinity and Metabolism of Benzbromarone-Based CYP2C19 Inhibitors. J. Med. Chem. 2004, 47, 6768-6776.
44. Wang, Q.; Halpert, J.R. Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modelling. Drug Metab. Disp. 2002, 30, 86-95.
45. Ekins, S.; Bravi, G.; Ring, B.J.; Gillespie, T.A.; Gillespie, J.S.; VandenBranden, M.; Wrighton, S.A.; Wikel, J.H. Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) analyses of substrates for CYP 2B6. J. Pharmacol. Exp. Ther. 1999, 288, 21-29.
46. Lesigiarska, I.; Pajeva, I.; Yanev, S. Quantitative Structure-Activity Relationship (QSAR) and Three-Dimensional QSAR Analysis of a Series of Xanthates as Inhibitors and Inactivators of Cytochrome P450 2B1. Xenobiotica 2002, 32, 1063-1077.
47. Poso, A.; Gynther, J.; Juvonen, R. A Comparative Molecular Field Analysis of Cytochrome P450 2A5 and 2A6 Inhibitors. J. Comput. Aid. Mol. Design 2001, 15, 195-202.
48. MacKenzie, P. I.; Owens, I. S.; Burchell, B.; Bock, K. W.; Bairoch, A.; Belanger, A. The UDP-glycosyltransferase gene superfamily-recommended nomenclature update based on evolutionary divergence, Pharmacogenetics 1997, 7, 255-269.
49. Ritter, J.K.; Crawford, J.M.; Owens, I.S. Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells. J Biol. Chem. 1991, 266, 1043-1047.
50. Ebner, T.; Remmel, R. P.; Burchell, B. Human bilirubin UDP-glucuronosyltransferase catalyses the glucuronidation of ethinylestradiol. Mol. Pharmacol. 1993, 43, 649-654.
51. Senafi, S.B.; Clarke, D.J.; Burchell, B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucurono-syltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 1994, 303, 233-240.
52. Sorich, M.J.; Smith, P.A.; McKinnon, R.A.; Miners, J.O. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates, Pharmacogenetics 2002, 12, 635-645.
53. Green, M. D.; Telphy, T. R. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalysed by expressed human Ugt1.4 Protein. Drug Metab. Dispos. 1996, 24, 356-363.
54. Green, M. D.; Bishop, W. P.; Telphy, T. R. Expressed Human UGT1.4 Protein Catalyses the Formation of Quaternary Ammonium-Linked Glucuronides. Drug Metab. Dispos. 1995, 23, 299-302.
55. Smith, P.A.; Sorich, M.J.; McKinnon, R.A.; Miners, J.O. Pharmacophore and quantitative structure activity relationship (QSAR) modelling: complementary approaches to the rationalisation and prediction of UDP-glucuronosyltransferase 1A4 (UGT1A4) substrate selectivity, J. Med. Chem. 2002, 46, 1617-1626.
56. Sorich, M.J.; Miners, J.O.; McKinnon, R.A.; Smith, P.A. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity, Mol. Pharm. 2004, 65, 301-308.
57. Ethel, B.T.; Ekins, S.; Wang, J.B.; Burchell, B. Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab. Dispos. 2002, 30, 734-738.
58. Sorich, M.J.; McKinnon, R.A.; Miners, J.O.; Smith, P.A. Comparison of linear and non-linear classification algorithms for the prediction of chemical metabolism by UDP-glucuronosyltransferase isoforms, J. Chem. Inform. Comp. Sci. 2003, 43, 2019-2024.
59. Sorich, M.J.; McKinnon, R.A.; Miners, J.O.; Winkler, D.A.; Smith, P.A. Rapid Prediction of Chemical Metabolism by Human UDP-glucuronosyltransferase Isoforms Using Quantum Chemical Descriptors Derived with the Electronegativity Equalisation Method. J. Med. Chem. 2004, 47, 5311-5317.
60. Hu, Y.N.; Walker, S. Remarkable structural similarities between diverse glycosyltransferases. Chem. Biol. 2002, 9, 1287-1296.
61. Van der Aar, E.M.; Bouwman, T.; Commandeur, J.N.M.; Vermeulen, N.P.E. Structure-activity relationships for chemical and glutathione S-transferase-catalysed glutathione conjugation reactions of a series of 2-substituted 1 chloro-4-nitrobenzenes. J. Biochem. 1996, 320, 531-540.